Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

ABSTRACT: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

DISEASE(S): Carcinoma,Sarcoma,Small Cell Lung Cancer,Small Cell Lung Carcinoma,Colorectal Cancer,Urothelial Carcinoma,Breast Cancer,Appendiceal Neoplasms,Esophagus Cancer,Pancreas Cancer,Esophageal Neoplasms,Nsclc,Appendix Cancer,Non-small Cell Lung Cancer,Gastric Cancer,Carcinoma, Ovarian Epithelial,Epithelial Ovarian Cancer,Solid Tumor, Adult,Pancreatic Neoplasms

PROVIDER: 2378763 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR